Pharmaceutical company Amneal Pharmaceuticals Inc (NYSE:AMRX) reported on Friday the receipt of US Food and Drug Administration (FDA) Abbreviated New Drug Application (ANDA) approval for 150 mcg/day Norelgestromin and 35 mcg/day Ethinyl Estradiol Transdermal System.
The company said it expects to begin commercialization activities with immediate effect.
Amneal added that the Norelgestromin and Ethinyl Estradiol Transdermal System is the generic version of the reference listed drug (RLD) Ortho Evra and will be marketed under the proprietary name Zafemy.
According to the company, Zafemy is a 12.5 cm2 patch indicated for the prevention of pregnancy in women with a Body Mass Index of less than 30 kg/m2 for whom a combined hormonal contraceptive is appropriate. It may be less effective in preventing pregnancy in women at or above 198 lbs (90 kg).
In connection with its approval of generic Ortho Evra, the company received a Competitive Generic Therapy (CGT) designation from the US FDA, with 180 days of exclusivity.
Additionally, Zafemy will provide patients with another option to the one equivalent product, Xulane, manufactured by Mylan. According to IQVIA, the US annual sales for Xulane for the 12 months ended December 2020 were approximately USD332m.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling